Addex Therapeutics: A Micro-Cap Bet on Repositioned Assets and a Hidden Equity Stake

Addex Therapeutics, a CHF 7 million market cap biotech, delivered a Q1 2026 update that is both routine and strategically revealing. The company continues to advance two key asset families — the mGlu5 negative allosteric modulator Dipraglurant for brain injury recovery, and a GABAB positive allosteric modulator for chronic cough — while wrestling with an extremely thin balance sheet. But the most interesting development is the potential monetization of its 20% equity stake in Neurosterix, a spinout whose valuation stands well above the parent's entire market cap.

Preclinical Momentum in Cough and Stroke

The cough program generated headlines this quarter. “We recently announced robust antitussive activity in a non human primate cost model as well as solid antitussive activity in an idiopathic pulmonary fibrosis model in guinea pigs.” — Timothy Mark Dyer, Chief Executive Officer · 2026-06-25 The data strengthen the case for a centrally-acting GABAB PAM as a potentially best-in-class therapy. Misha highlighted that chronic treatment with the compound reduced cough by 40–60% in the IPF model, and importantly, reduced lung fibrosis as measured by Ashcroft scores. The guinea pig model remains the workhorse, but the NHP confirmation adds credibility. The compound also appears to have a wide therapeutic margin: “Compound A was well tolerated as there were no marked changes in respiratory rate at up to 60 mg per kg.” — Mikhail Kalinichev, Head of Translational Science · 2026-06-25 This contrasts with the respiratory depression seen with reference drugs like nalbuphine and baclofen. The company is now evaluating the candidate in rabbits as part of its preclinical profiling.

However, the path to the clinic is gated by funding. The CEO was explicit:

On a going concern basis. However, current cash does not fund the progression of our unpartnered programs into the clinic.

The Dipraglurant Repositioning

Dipraglurant, an mGlu5 NAM, is being repositioned for post-stroke and traumatic brain injury recovery. This is not a new theme — the company has talked about it for several quarters — but this quarter it emphasized progress under the Sinntaxis collaboration and the University of Lund. The mechanism, inhibition of mGlu5 to promote adaptive rewiring, is supported by data showing improved sensorimotor function in rats and enhanced intra/interhemispheric connectivity. The respiratory rate safety biomarker from the cough program is unrelated, but the emphasis on translational biomarkers is consistent across both franchises.

The real strategic question revolves around Neurosterix. Addex spun out its preclinical neuropsychiatric assets in 2024, keeping a 20% stake. Neurosterix has since advanced its M4 PAM (NTX-53) into Phase 1 and selected a backup. The market cap of Addex is ~CHF 8 million, while the 20% stake was valued at ~CHF 20 million at the funding round. This disconnect is glaring. In response to an analyst question, the CEO acknowledged inbound interest and the possibility of monetizing the stake to fund the cough program: “One strategy could be to monetize the Neurosterics interest and sell it and to then use the proceeds to invest in our COF program.” — Timothy Mark Dyer, Chief Executive Officer · 2026-06-25 This is the most significant potential catalyst for the stock.

A Thin Financial Foundation

The company's financials are skeletal. Operating loss was CHF 0.5 million in Q1 2026, with cash burn of CHF 0.77 million. The balance sheet shows only CHF 0.9 million cash. The company has an ATM facility and raised a small amount in Q2. The antitussive efficacy data are promising, but without financing, these programs stall.

Prior calls have already flagged the cash constraints. In December 2025, the CEO noted, “We know from our discussions with KOLs that baclofen is efficacious in cough patients.” — Timothy Dyer, Chief Financial Officer · 2025-12-04 This quarter, the company is closer to IND-enabling studies, but the funding gap remains the central bottleneck. The analyst also probed the P2X3 mechanism, and the company reiterated that the distinct nonresponder population remains a target: “there are up to 50% of patients that have no benefit from this mechanism.” — Mikhail Kalinichev, Head of Translational Science · 2025-12-04 These considerations underscore the commercial opportunity, but also the execution risk.

Conclusion

Addex is a micro-cap with a binary outcome. The preclinical data are encouraging, particularly the IPF fibrosis reduction and the NHP cough efficacy. The company's hidden asset — the Neurosterix stake — could be the key to unlocking value. If the company can monetize that stake and fund its own programs, it could become a more meaningful player in CNS and cough. If not, it faces a going-concern risk. Investors should watch for the Q3 Phase 1 data from Neurosterix and any announcement regarding the equity stake.